Risk Management for Clinical LabsAs CLIA Turns 20, A New QC Paradigm Lies Ahead for Labs By Bill Malone
Though lab directors manage risks in their labs every day, CLSI is working on guidelines that will formalize risk management and possibly open up a new way to meet CLIA QC requirements.
Tissue of Origin Test for Metastatic CancerIs This the Beginning of Genomic-based Cancer Analysis? By Gina Rollins
Despite advances in laboratory and imaging studies, identification of a patient’s primary tumor site remains elusive in more than 70% of cases. Now FDA’s recent clearance of a first of its kind test to determine the original tumor site may improve treatment options.
Circulating Tumor CellsA New Opportunity for Therapeutic Management of Cancer Patients By Martin Fleisher, PhD, FACB
In the metastatic process, tumor cells break away from the primary tumor and traverse the circulation to colonize distant organs. Emerging analytical techniques have enabled the analysis of these circulating tumor cells, bringing a new opportunity for labs to have a significant impact on therapeutic management of cancer patients.
Recommendations Revised for Colorectal Cancer Screening
Catherine Hammett-Stabler Elected 2010 AACC President
News from the FDA
Download the entire issue
Screening for Diabetes with HbA1c
The Surge of Lab-developed Tests